Meta-analysis of efficacy and safety of custirsen in patients with metastatic castration-resistant prostate cancer

Custirsen is the second-generation antisense oligonucleotide (ASO), which can reduce cellular levels of clusterin to increase the cytotoxic effect of chemotherapeutic drugs. Our study assessed the efficacy and safety of custirsen in patients with metastatic castration-resistant prostate cancer (mCRP...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Xuebao, Liu, Chu, Li, Kui, Wang, Ke, Zhang, Qiqiang, Cui, Yuanshan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6380863/
https://www.ncbi.nlm.nih.gov/pubmed/30732140
http://dx.doi.org/10.1097/MD.0000000000014254

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6380863/
https://www.ncbi.nlm.nih.gov/pubmed/30732140
http://dx.doi.org/10.1097/MD.0000000000014254

Ejemplares similares